Genetic variations of the apolipoprotein E gene determine the plasma triglyceride levels after heart transplantation

J Heart Lung Transplant. 2000 Aug;19(8):765-70. doi: 10.1016/s1053-2498(00)00131-5.

Abstract

Objectives: To study whether the presence of the polymorphism in the apolipoprotein E (apo E) gene influences the lipid profile in heart-transplant recipients.

Methods: A cohort of 103 recipients of heart transplant (93 men and 10 women, with a mean age of 47 +/- 13 years) under triple immunosuppressive therapy were submitted to a genetic study of the apo E gene region. Anthropometric and analytical data, including lipid profile and arterial blood pressure were collected prior to transplantation and 3, 6, 12, and 24 months after it.

Results: 65 subjects present the genotype E3E3, 27 the genotype E3E4, 6 the genotype E2E3, and 5 the genotype E2E4. Carriers of the E2 allele (that is, genotypes E3E2 and E4E2) had higher total plasma triglyceride (TG) levels after 3 months (3.47 +/- 1.88 mmol/liter p < 0.001) and after 1 year of transplantation (3.13 +/- 1.77 mmol/liter p < 0.05) than the other genotypes. There were no differences in the plasma levels of total cholesterol (TC), LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C). Multiple regression analysis revealed that the apoprotein E gene polymorphism determines 5% (p = 0.0425) and age 8.7% (p < 0.009) of the variants in TG levels.

Conclusions: The presence of the E2 allele in heart-transplant recipients produces a greater rise in total TG plasma levels than the other genotypes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein A-I / blood
  • Apolipoproteins B / blood
  • Apolipoproteins E / genetics*
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • Genetic Variation*
  • Genotype
  • Heart Transplantation / immunology
  • Heart Transplantation / physiology*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Triglycerides / blood*

Substances

  • Apolipoprotein A-I
  • Apolipoproteins B
  • Apolipoproteins E
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Immunosuppressive Agents
  • Triglycerides
  • Cholesterol